Physicians Complain Of N.Z. Slowness In Approving Drugs
This article was originally published in PharmAsia News
Executive Summary
Diabetes experts in New Zealand complain the nation's drug-buying agency is too restrictive with its investments in drugs, causing unnecessary harm. The group said Pharmac funding for diabetes drugs and supplies has decreased in recent years even as the country faces a diabetes epidemic. The signer of a physicians' letter to Pharmac said clinicians were frustrated by the agency's lack of progress, and added it took four years to approve ace inhibitors and ARBS to protect kidneys. (Click here for more